阿美替尼联合吉西他滨、顺铂化疗治疗晚期非小细胞肺癌患者的疗效

doi:10.3969/j.issn.1671-7171.2025.09.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1252 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of aumetinib combined with gemcitabine and cisplatin chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).【Methods】 A total of 194 patients with advanced NSCLC were randomly divided into the observation group(98 cases) and the control group(96 cases). The control group received gemcitabine and cisplatin chemotherapy, while the observation group was additionally treated with aumetinib in addition to the control regimen. The efficacy, drug safety, one-year survival, as well as changes in tumor markers, pulmonary function, and immune function before and after treatment were compared between the two groups.【Results】 The objective response rate and disease control rate in the observation group were significantly higher than those in the control group(P<0.05). After treatment, the levels of tumor biomarkers in the observation group were significantly lower than those in the control group(P<0.05). Forced vital capacity(FVC) and the ratio of forced expiratory volume in one second to FVC(FEV₁/FVC) were also higher in the observation group(P<0.05). The ratios of Th1/Th2 and Th17/Treg were significantly lower, while the CD4⁺/CD8⁺ ratio was higher in the observation group compared to the control group(P<0.05). There was no statistically significant difference in the overall incidence of adverse drug reactions between the two groups(P>0.05). Kaplan-Meier survival analysis showed better survival outcomes in the observation group(P<0.05).【Conclusion】 Aumetinib combined with gemcitabine and cisplatin chemotherapy significantly improves short-term treatment efficacy in patients with advanced NSCLC, effectively reduces tumor marker levels, helps restore pulmonary ventilation function, modulates immune response, and demonstrates good safety.

Key words： Carcinoma, Non-Small-Cell Lung Cisplatin Antineoplastic Agents Treatment Outcome

Received: 20 May 2025

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xiancheng
	LI Hongmiao

Cite this article:

WU Xiancheng,LI Hongmiao. Efficacy of Aumetinib Combined with Gemcitabine and Cisplatin Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1498-1501.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.09.003 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I9/1498

[1] MITHOOWANI H, FEBBRARO M. Non-Small-Cell Lung Cancer in 2022:a review for general practitioners in oncology[J].Curr Oncol,2022, 29(3):1828-1839.
[2] 左强, 江国强, 方芳, 等. 伏美替尼治疗EGFR突变阳性非小细胞肺癌EGFR-TKI耐药患者的临床观察[J].中国现代医学杂志, 2022, 32(14):30-34.
[3] ETTINGER D S, WOOD D E, AISNER D L, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022, 20(5):497-530.
[4] CHEN W Y, ZHANG L J, SHEN H, et al. Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease:a case report and literature review[J].Anticancer Drugs,2023, 34(3):460-466.
[5] 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志, 2021, 43(6):591-621.
[6] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[7] HIGGINS K A, PURI S, GRAY J E. Systemic and radiation therapy approaches for locally advanced Non-Small-Cell lung cancer[J].J Clin Oncol,2022, 40(6):576-585.
[8] LIU L, LI W, YANG L, et al. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers[J].Acta Pharmacol Sin,2022, 43(4):1082-1090.
[9] WANG R L, YU S, YU L M, et al. Case report:sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients[J].Transl Cancer Res,2022, 11(6):1836-1843.
[10] 石功亮,颜艳倩.表皮生长因子受体酪氨酸激酶抑制剂靶向治疗肺癌患者的临床效果及其对患者肺功能指标的影响[J].临床合理用药杂志,2022,15(3):1-4.
[11] LU S, DONG X R, JIAN H, et al. AENEAS:a randomized phase Ⅲ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic Non-Small-Cell lung cancer with EGFR Exon 19 deletion or L858R mutations[J].J Clin Oncol,2022, 40(27):3162-3171.
[12] 韩倩, 苏凤云, 宋争昌, 等. 阿美替尼片治疗晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志, 2022, 38(15):1723-1726.
[13] 许涛,金忠文,叶辉.射频消融联合EGFR-TKI靶向治疗老年NSCLC患者的效果分析[J].中国药物滥用防治杂志,2022,28(11):1654-1657.
[14] TAN S, LU R, YAO D, et al. Identification of LRRK2 inhibitors through computational drug repurposing[J].ACS Chem Neurosci,2023, 14(3):481-493.